Squibb
Executive Summary
Licenses BVaraU antiviral agent from Yamsa Shoyu of Japan. BVaraU is being investigated for treating shingles and cold sores caused by the herpes zoster and herpes simplex virus. Squibb filed for an IND in February; clinical trials are expected to begin in the U.S. and Europe in late 1989.